阅读说明：本技术 病理性炎症的新医学治疗 (Novel medical treatment of pathological inflammation ) 是由 G·赫德隆 A·比约克 于 2019-08-15 设计创作，主要内容包括：式(I)化合物或其药学上可接受的盐或溶剂化物,与5-ASA剂组合用于治疗由病理性炎症引起的疾病。式(I)化合物或其药学上可接受的盐或溶剂化物与5-ASA剂的组合,以及此类组合的用途。包含此类组合的多组件药盒和药物组合物。(A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, in combination with a 5-ASA agent for use in the treatment of a disease caused by pathological inflammation.A combination of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and a 5-ASA agent, and the use of such a combination. A kit of parts and a pharmaceutical composition comprising such a combination.)

1. Use of a compound of formula (I) in combination with a 5-ASA agent for the treatment of a disease caused by pathological inflammation

Or a pharmaceutically acceptable salt or solvate thereof; wherein

R₁Selected from C1-C6 alkyl and C3-C6 cycloalkyl;

R₂selected from H and C1-C3 alkyl;

R₃、R₄、R₅and R₆Independently selected from hydrogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, halogen, phenyl and benzyl, wherein any alkyl is optionally substituted with one or more fluoro;

R₇selected from hydrogen and C1-C3 alkyl;

R₈and R₉Independently selected from C1-C6 alkyl, or

R₈And R₉Together with the nitrogen atom to which they are both attached form the following moiety:

formula (II)

；

r is 0 or 1;

R₁₀selected from C1-C3 alkyl and C3-C4 cycloalkyl; said alkyl and cycloalkyl groups being optionally substituted by hydroxy, halogen, cyano, COOR₁₂Or NHR₁₃Substitution;

q is selected from CHR₁₁、NR₁₁And O;

R₁₁selected from hydrogen, C1-C3 alkyl, and C3-C4 cycloalkyl; said alkyl and cycloalkyl groups being optionally substituted by hydroxy, halogen, cyano, COOR₁₂Or NHR₁₃Substitution;

R₁₂and R₁₃Independently selected from hydrogen, C1-C3 alkyl, and C3-C4 cycloalkyl;

when Q is CHR₁₁When p is 1,2 or 3; and is

When Q is selected from NR₁₁And when O, p is 2 or 3.

2. A compound or pharmaceutically acceptable salt or solvate for use according to claim 1, wherein

R₃、R₄、R₅And R₆Independently selected from hydrogen, C1-C2 alkyl, C1-C2 alkoxy, C1-C2 alkylthio, halogen and trifluoroA methyl group;

R₇selected from hydrogen and C1-C3 alkyl;

R₈and R₉Independently selected from C1-C6 alkyl, or

R₈And R₉Together with the nitrogen atom to which they are both attached form the following moiety:

formula (II)

；

r is 0 or 1;

R₁₀selected from C1-C3 alkyl and C3-C4 cycloalkyl;

q is CHR₁₁；

R₁₁Selected from hydrogen and C1-C3 alkyl;

or a pharmaceutically acceptable salt or solvate thereof.

3. A compound or pharmaceutically acceptable salt or solvate for use according to claim 1 or 2, wherein

R₁Selected from C1-C3 alkyl;

R₂、R₄、R₅、R₆and R₇Each of which is hydrogen; and is

R₈And R₉Independently selected from C1-C4 alkyl.

4. A compound or pharmaceutically acceptable salt or solvate for use according to any one of claims 1 to 3, wherein the compound of formula (I) is selected from

4-acetylamino-3-chloro-N- [2- (diethylamino) ethyl ] benzamide,

4-propionylamino-3-chloro-N- [2- (diethylamino) ethyl ] benzamide,

4-isobutyramido-3-chloro-N- [2- (diethylamino) ethyl ] benzamide,

4-acetylamino-N- [2- (diethylamino) ethyl ] benzamide,

n- [2- (diethylamino) ethyl ] -4- (propionylamino) benzamide, and

n- [2- (diethylamino) ethyl ] -4- (isobutyramido) benzamide.

5. The compound or pharmaceutically acceptable salt or solvate for use according to claim 4, wherein the compound of formula (I) is 4-acetamido-3-chloro-N- [2- (diethylamino) ethyl ] benzamide.

6. The compound or pharmaceutically acceptable salt or solvate for use according to any one of claims 1 to 5, wherein the 5-ASA agent is a formulation capable of releasing 5-ASA or a salt or solvate thereof in vivo.

7. The compound or pharmaceutically acceptable salt or solvate for use according to any one of claims 1 to 5, wherein the 5-ASA agent is selected from mesalamine, sulfasalazine, olsalazine and balsalazide.

8. The compound or pharmaceutically acceptable salt or solvate for use according to any one of claims 1 to 7, wherein the disease is inflammatory bowel disease.

9. The compound or pharmaceutically acceptable salt or solvate for use according to claim 8, wherein the inflammatory bowel disease is ulcerative colitis.

10. The compound or pharmaceutically acceptable salt or solvate for use according to claim 8, wherein the inflammatory bowel disease is Crohn's disease.

11. (iii) a combination of (i) and (ii) below:

(i) a compound of formula (I)

Or a pharmaceutically acceptable salt or solvate thereof; wherein

R₁Selected from C1-C6 alkyl and C3-C6 cycloalkyl;

R₂selected from H and C1-C3 alkyl;

R₃、R₄、R₅and R₆Independently selected from hydrogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, halogen, phenyl and benzyl, wherein any alkyl is optionally substituted with one or more fluoro;

R₇selected from hydrogen and C1-C3 alkyl;

R₈and R₉Independently selected from C1-C6 alkyl, or

R₈And R₉Together with the nitrogen atom to which they are both attached form the following moiety:

formula (II)

；

r is 0 or 1;

R₁₀selected from C1-C3 alkyl and C3-C4 cycloalkyl; said alkyl and cycloalkyl groups being optionally substituted by hydroxy, halogen, cyano, COOR₁₂Or NHR₁₃Substitution;

q is selected from CHR₁₁、NR₁₁And O;

R₁₁selected from hydrogen, C1-C3 alkyl, and C3-C4 cycloalkyl; said alkyl and cycloalkyl groups being optionally substituted by hydroxy, halogen, cyano, COOR₁₂Or NHR₁₃Substitution;

R₁₂and R₁₃Independently selected from hydrogen, C1-C3 alkyl, and C3-C4 cycloalkyl;

when Q is CHR₁₁When p is 1,2 or 3; and is

When Q is selected from NR₁₁And when O, p is 2 or 3; and

(ii) 5-ASA agent.

12. The combination of claim 11, wherein

R₃、R₄、R₅And R₆Independently selected from hydrogen, C1-C2 alkyl, C1-C2 alkoxy, C1-C2 alkylthio, halogen and trifluoromethyl;

R₇selected from hydrogen and C1-C3 alkyl;

R₈and R₉Independently selected from C1-C6 alkyl, or

R₈And R₉Together with the nitrogen atom to which they are both attached form the following moiety:

formula (II)

；

r is 0 or 1;

R₁₀selected from C1-C3 alkyl and C3-C4 cycloalkyl;

q is CHR₁₁；

R₁₁Selected from hydrogen and C1-C3 alkyl;

or a pharmaceutically acceptable salt or solvate thereof.

13. Combination according to claim 11 or 12, wherein

R₁Selected from C1-C3 alkyl;

R₂、R₄、R₅、R₆and R₇Each of which is hydrogen; and is

R₈And R₉Independently selected from C1-C4 alkyl.

14. The combination according to any one of claims 11 to 13, wherein the compound of formula (I) is selected from

4-acetylamino-3-chloro-N- [2- (diethylamino) ethyl ] benzamide,

4-propionylamino-3-chloro-N- [2- (diethylamino) ethyl ] benzamide,

4-isobutyramido-3-chloro-N- [2- (diethylamino) ethyl ] benzamide,

4-acetylamino-N- [2- (diethylamino) ethyl ] benzamide,

n- [2- (diethylamino) ethyl ] -4- (propionylamino) benzamide, and

n- [2- (diethylamino) ethyl ] -4- (isobutyramido) benzamide.

15. A combination according to claim 14 wherein the compound of formula (I) is 4-acetamido-3-chloro-N- [2- (diethylamino) ethyl ] -benzamide.

16. The combination according to any one of claims 11 to 15, wherein the 5-ASA agent is a formulation capable of releasing 5-ASA or a salt or solvate thereof in vivo.

17. The combination according to any one of claims 11 to 15, wherein the 5-ASA agent is selected from mesalamine, sulfasalazine, olsalazine and balsalazide.

18. A pharmaceutical composition comprising a combination according to any one of claims 11 to 17 and optionally a pharmaceutically acceptable excipient.

19. A kit of parts comprising a combination according to any one of claims 11 to 16, wherein each of component (i) and component (ii) is optionally formulated in admixture with a pharmaceutically acceptable excipient.

20. Use of a compound of formula (I) according to any one of claims 1 to 5 in the manufacture of a medicament for the treatment of a disease caused by pathological inflammation, wherein the treatment further comprises administration of a 5-ASA agent.

21. A method of treating a disease caused by pathological inflammation, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula (I) as claimed in any one of claims 1 to 5, or a salt or solvate thereof, wherein the treatment further comprises the administration of a 5-ASA agent.

Technical Field

The present invention relates to compounds useful for treating diseases caused by pathological inflammation. More particularly, the present invention relates to 4-alkanoylaminobenzamide derivatives in combination with 5-aminosalicylate (5-ASA) agents for the treatment of Inflammatory Bowel Disease (IBD). Furthermore, the present invention relates to combinations of 4-alkanoylaminobenzamide derivatives and 5-ASA agents, as well as pharmaceutical formulations and kit-of-parts (kit-of-parts) comprising such combinations.

Background

Throughout this application, various (non-patent) publications are referenced by first author and year of publication. The complete citations of these publications are given in the reference section immediately preceding the claims. The disclosures of these documents and publications referred to herein are hereby incorporated by reference in their entirety into this application in order to more fully describe the state of the art to which this invention pertains.

Inflammatory Bowel Disease (IBD)

IBD, which consists primarily of Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic, frequently progressive gastrointestinal condition that requires life-long treatment. The natural history of this condition is one of the remission periods, interrupted by the recurrence of disease activity. CD and UC are diseases with many similarities, but often differ in location and how they are managed. UC is characterized by recurrent and remitting mucosal inflammation, starting from the rectum and extending to the proximal segment of the colon, and its histology is characterized by the presence of both acute and chronic inflammation. Diagnosis of UC is based on a combination of symptoms, endoscopic findings, and histology. Pathogenesis is multifactorial, including genetic susceptibility, immune response disorders, and environmental factors. CD may relate to any part of the gastrointestinal system. Approximately 60% of CD patients suffer from colon involvement. Half of these patients have disease restricted to the colon (Mills, 2007).

Depending on the extent of the disease, patients with UC may be classified as having 1) ulcerative proctitis that only affects the rectum, 2) left UC that affects the colorectum distal to the splenic flexure, and 3) extensive UC that affects the colon proximal to the splenic flexure (including pan colitis). Symptoms may vary depending on the extent and extent of inflammation. Patients are classified as having mild, moderate, or severe disease activity based on one or more measures of disease severity. The hallmark symptom of UC is hemorrhagic diarrhea with stool urgency. Other symptoms include abdominal cramps, loss of appetite, fatigue, weight loss, and fever. Traditionally, the highest incidence of both CD and UC is found in developed countries in north america and europe. The prevalence is estimated to be 70-500 per 100,000 people, with men and women affected similarly. People are more often diagnosed with UC between the ages of 15 and 35, and have a second, smaller peak between the ages of 55 and 65. Median age at diagnosis was 30 years. In 15% of cases, UC is diagnosed in childhood and may be present before school age. CD and UC bring significant costs to the health care system and society.

UC has a substantial impact on the quality of life of patients due to early onset and lack of cure. Current drugs are moderately effective and side effects are a problem. Therefore, there is an urgent need to improve clinical management by establishing new therapeutic strategies. The therapeutic goals are to induce and maintain remission and to prevent complications. Patients with mucosal healing with no or very mild signs and symptoms are considered to be in remission. The ultimate therapeutic goal for all patients with UC is steroid-free clinical and endoscopic remission. The impact on the inflammatory process is essential, since the lack of inflammatory control even in the presence of symptomatic control is associated with poor long-term outcomes. The risk of colectomy and colorectal cancer is increased in patients who do not respond to medical management. The extra-intestinal manifestations of UC include primary sclerosing cholangitis, as well as joint, skin and eye manifestations.

Treatment of IBD

Treatment recommendations depend on the location of the disease, severity of the disease, and complications of the disease. First line treatment of mild to moderate UC involves the administration of a 5-aminosalicylate (5-ASA; mesalamine [ CAS No. 89-57-6]) agent. Sulfasalazine (SASP [ CAS number 599-79-1]), an azo-bonded prodrug of 5-ASA, is the parent 5-ASA agent. SASP provides modest benefit for the treatment of mild to moderate active CD (Lim, 2016). Patients with ineffective or incomplete response to 5-ASA drugs can be treated with corticosteroids or immunomodulators (thiopurines). Tumor necrosis factor-alpha (TNF α) blockers are useful in treating patients with UC that have moderate to severe activity, as well as patients with UC that have failed conventional therapy. However, serious side effects limit the use of these types of drugs. Clearly, there is a clear need for new drugs with higher efficacy and safety to induce and then maintain clinical and endoscopic remission.

5-ASA in UC

The primary therapy for mild to moderate UC is 5-ASA agent (Hanauer, 2004). After the introduction of SASP (Svartz 1942), the successful management of UC is very convenient. It is generally believed that 5-ASA represents the therapeutically active portion of SASP (Azad khan 1977; van Hees 1980). Orally ingested SASP is enzymatically decomposed in the colon into 5-ASA and sulfapyridine (CAS number 144-83-2) (Peppercorn 1972), thereby releasing 5-ASA which acts locally on the colonic mucosa. Other azo-bonded 5-ASA agents include olsalazine (CAS number 15722-48-2) and balsalazide (CAS number 80573-04-2). Other 5-ASA delivery systems use, for example, pH dependent delayed release formulations to directly release sufficient concentrations of 5-ASA in the colon (Amidon 2015). Both oral and rectal therapies are effective in inducing and maintaining remission. Once daily is the optimal dose and there is marginal evidence of significant dose-response effects beyond 2400 mg/day.

Systematic review and meta-analysis of patients with active mild to moderate UC comparing 5-ASA to placebo indicates that 5-ASA is significantly superior to placebo (Wang 2016 a; Wang 2016 b). 71% of 5-ASA patients failed to enter clinical remission, compared to 83% of placebo patients. 5-ASA was also found to be superior to placebo in maintenance therapy. 41% of 5-ASA patients relapse compared to 58% of placebo patients. No statistically significant difference in efficacy in inducing remission was found between 5-ASA and SASP (Wang 2016 a). However, SASP was found to be significantly superior to 5-ASA (Wang 2016b) in maintaining remission.

Mechanism of action of 5-ASA

The mechanism by which 5-ASA agents act is not known, but the central mechanism explaining the inhibitory effect of 5-ASA on various inflammatory pathways may be due to its inhibition of nuclear factor κ B (nfkb) activation (MacDermott, 2000). SASP has been shown to be a potent inhibitor of NF κ B activation, to inhibit NF κ B-dependent transcription, and to prevent nuclear translocation of NF κ B due to inhibition of inhibitory κ B α (I κ B α) phosphorylation and subsequent degradation (Wahl, 1998; Zhao, 2010). 5-ASA has been shown to inhibit TNF α -stimulated NF κ B activation, NF κ B nuclear translocation, and I κ B α degradation (Kaiser, 1999).

Activation of NF kappa B

NF κ B is considered to be a heterodimer of proteins belonging to the Rel family of Transcription Factors (TFs). A common feature of the regulation of TFs belonging to the Rel family is that they chelate in the cytoplasm as inactive complexes with a class of inhibitory molecules called I κ B. Treatment of cells with different inducers (e.g., TNF α) results in dissociation of the cytoplasmic complex and translocation of free nfkb to the nucleus. There are two major biochemically characterized forms of I κ B protein in mammalian cells-I κ B α and I κ B β. The main difference between I κ B α and I κ B β is their response to different inducers of NF κ B activity. One class of inducers causes rapid but transient activation of nfkb by primarily affecting the I κ B α complex, while another class of inducers causes durable activation of nfkb by affecting both the I κ B α complex and the I κ B β complex. Thus, overall activation of NF κ B consists of two overlapping phases, i.e., a transition phase mediated by I κ B α and a duration mediated by I κ B β. Upon stimulation, the differential behavior of the two I κ bs fulfills the promption of differential regulation suggested by the presence of multiple I κ B isoforms. Although the two major I κ B isoforms interact with the same Rel protein, they are activated by different signaling pathways, possibly leading to very different physiological responses. While the I κ B α response is used to immediately respond to transient stress states, the sustained response produced by I κ B β may be used in chronic inflammatory, infectious, stress or differentiated states (Thompson, 1995).

4-aminobenzamides

4-aminobenzamides, including metoclopramide (CAS No. 364-62-5) and procainamide (CAS No. 51-06-9), constitute a class of compounds that have been developed for many clinical indications and are screened or used as antiemetics, antiarrhythmics, local anesthetics, anti-inflammatory agents, antineoplastics, and radiation/chemosensitizers (Stanley, 1982; Rang, 1995; Pero, 1998, and 1999). The diverse clinical applications of these drugs are paralleled by the equally diverse patterns of action profiles. U.S. patent No. 3,177,252 discloses 4-aminobenzamides for the treatment of emesis and behavioral disorders. Metoclopramide belongs to the class of dopamine antagonists. EP 0927030B 1 includes the use of dichloropramine (CAS number 891-60-1) to inhibit or kill tumors or cancer cells. Among the many small molecule NF κ B inhibitors, desclopramide is listed as a potential therapeutic agent for the treatment of autoimmune diseases, including IBD (Ivanenkov, 2011). A combination of 5-ASA and procainamide was used in an attempt to improve the anti-colitis efficacy of 5-ASA. Rectal administration of combined 5-ASA and procainamide resulted in an additive anti-colitis effect in the 2,4, 6-trinitrobenzenesulfonic acid induced rat colitis model (Kim, 2016). Neither rectal administration of combined 5-ASA and procainamide, nor oral administration of 5-ASA azo-bonded to procainamide (5-ASA-azo-PA) showed advantages over oral SASP alone.

The well-known risk of potentially serious neurological and cardiovascular adverse events and antinuclear antibody formation may outweigh the potential clinical benefit of using 4-aminobenzamide in long-term therapy (Harrington, 1983; Harron, 1990).

4-alkanoylaminobenzamides

U.S. patent No. 3,177,252 discloses 4-alkanoylaminobenzamides for the treatment of emesis and behavioral disorders. WO 99/63987 discloses 4-acetamido-3-chloro-N- [2- (diethylamino) ethyl ] benzamide (N-acetyl chloropromide; hereinafter Compound A) and its use to inhibit or kill tumor or cancer cells and as a potential therapeutic agent for the treatment of inflammatory disorders. N-acetylprocainamide (CAS number 32795-44-1) has been used for the treatment or prevention of cardiac arrhythmias.

4-aminobenzamides are known to inhibit NF κ B, and these compounds have also been found to induce apoptosis (Liberg, 1999). Acetylation of desloramine to give compound A abrogated the induction of apoptosis (Liberg 1999; Lindgren 2003), but nevertheless significantly enhanced NF κ B inhibition compared to the corresponding 4-aminobenzamide (Liberg, 1999; Lindgren, 2001). While 4-aminobenzamides inhibited both I κ B α degradation and NF κ B rescue pathway, 4-alkanoylaminobenzamide analogs inhibited I κ B β degradation and did not affect the NF κ B rescue pathway (Lindgren, 2003).

Disclosure of Invention

One aspect is the use of a compound of formula (I) in combination with a 5-ASA agent for the treatment of a disease caused by pathological inflammation

Or a pharmaceutically acceptable salt or solvate thereof; wherein

R₁Selected from C1-C6 alkyl and C3-C6 cycloalkyl;

R₂selected from H and C1-C3 alkyl;

R₃、R₄、R₅and R₆Independently selected from hydrogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, halogen, phenyl and benzyl, wherein any alkyl is optionally substituted with one or more fluoro;

R₇selected from hydrogen and C1-C3 alkyl;

R₈and R₉Independently selected from C1-C6 alkyl, or

R₈And R₉Together with the nitrogen atom to which they are both attached form the following moiety:

formula (II)

；

r is 0 or 1;

R₁₀selected from C1-C3 alkyl and C3-C4 cycloalkyl; said alkyl and cycloalkyl groups being optionally substituted by hydroxy, halogen, cyano, COOR₁₂Or NHR₁₃Substitution;

q is selected from CHR₁₁、NR₁₁And O;

R₁₁selected from hydrogen, C1-C3 alkyl, and C3-C4 cycloalkyl; said alkyl and cycloalkyl groups being optionally substituted by hydroxy, halogen, cyano, COOR₁₂Or NHR₁₃Substitution;

R₁₂and R₁₃Independently selected from hydrogen, C1-C3 alkyl, and C3-C4 cycloalkyl;

when Q is CHR₁₁When p is 1,2 or 3; and is

When Q is selected from NR₁₁And when O, p is 2 or 3.

One aspect is a combination of (i) and (ii) below:

(i) a compound of formula (I)

Or a pharmaceutically acceptable salt or solvate thereof; wherein

R₁Selected from C1-C6 alkyl and C3-C6 cycloalkyl;

R₂selected from H and C1-C3 alkyl;

R₃、R₄、R₅and R₆Independently selected from hydrogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, halogen, phenyl and benzyl, wherein any alkyl is optionally substituted with one or more fluoro;

R₇selected from hydrogen and C1-C3 alkyl;

R₈and R₉Independently selected from C1-C6 alkyl, or

R₈And R₉Together with the nitrogen atom to which they are both attached form the following moiety:

formula (II)

；

r is 0 or 1;

R₁₀selected from C1-C3 alkyl and C3-C4 cycloalkyl; said alkyl and cycloalkyl groups being optionally substituted by hydroxy, halogen, cyano, COOR₁₂Or NHR₁₃Substitution;

q is selected from CHR₁₁、NR₁₁And O;

R₁₁selected from hydrogen, C1-C3 alkyl, and C3-C4 cycloalkyl; said alkyl and cycloalkyl groups being optionally substituted by hydroxy, halogen, cyano, COOR₁₂Or NHR₁₃Substitution;

R₁₂and R₁₃Independently selected from hydrogen, C1-C3 alkyl, and C3-C4 cycloalkyl;

when Q is CHR₁₁When p is 1,2 or 3; and is

When Q is selected from NR₁₁And when O, p is 2 or 3; and

(ii) 5-ASA agent.

Another aspect is a pharmaceutical composition comprising a combination as defined herein and optionally a pharmaceutically acceptable excipient. The compositions are useful for treating pathological inflammation, particularly IBD.

Another aspect is a kit of parts comprising a combination as defined herein, wherein each of the components (i) and (ii) is optionally formulated in admixture with a pharmaceutically acceptable excipient. The kit of parts is useful for the treatment of pathological inflammation, and in particular for the treatment of IBD.

Yet another aspect of the invention is the use of a compound of formula (I) or a salt or solvate thereof as defined herein, in the manufacture of a medicament for the treatment of a disease caused by pathological inflammation, wherein the treatment further comprises the administration of a 5-ASA agent.

Yet another aspect of the present invention is the use of a compound of formula (I) or a salt or solvate thereof as defined herein, in the manufacture of a medicament for the treatment of a disease caused by pathological inflammation, wherein the medicament further comprises a 5-ASA agent.

Yet another aspect is the use of a compound of formula (I) or a salt or solvate thereof and a 5-ASA agent in the manufacture of a kit of parts for the treatment of pathological inflammation, such as IBD.

Another aspect is a method of treating a disease caused by pathological inflammation comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula (I) or a salt or solvate thereof in combination with administration of a 5-ASA agent to said mammal.

Other features and advantages of the present invention will be understood by reference to the following detailed description and examples.

Detailed Description

Definition of

As used herein, and unless otherwise stated or otherwise apparent from the context, each of the following terms shall have the definition set forth below.

The term "Cn alkyl" refers to a straight or branched chain saturated hydrocarbon group containing n carbon atoms in the chain, i.e., formula C_nH_2n+1Part (c) of (a).

The term "Cn-Cm alkyl" refers to a straight or branched chain alkyl group containing a number of carbon atoms in the range of n to m in the chain, where n and m are both integers and m is higher than n.

The term "Cn cycloalkyl" refers to formula C_nH_2n-1A cyclic hydrocarbon group of (2).

The term "Cn-Cm cycloalkyl" refers to a cyclic hydrocarbon group containing a number of carbon atoms in the ring in the range of n to m, where n and m are both integers and m is higher than n.

The term "Cn-Cm alkoxy" refers to a moiety of the formula

Wherein R is Cn-Cm alkyl. For example, methoxy is C1 alkoxy.

The term "Cn-Cm alkylthio" refers to a moiety of the formula

Wherein R is Cn-Cm alkyl. For example, methylthio is C1 alkylthio.

The term "halogen" means F, Cl, Br or I; f, Cl or Br is preferred.

The term "hydroxy" refers to the following moiety

。

The term "phenyl" refers to a group of the formula

。

The term "benzyl" refers to a group of the formula

。

As used herein, "AABZ" means a compound of formula (I) as described herein. Unless otherwise indicated or apparent from the context, the term also includes pharmaceutically acceptable salts or solvates (including hydrates) thereof.

As used herein, in the context of a numerical value or range, "about" means ± 20% of the numerical value or range recited or claimed.

As used herein, "add" or "add therapy" means that a collection of agents is used in therapy, wherein a subject receiving the therapy begins a first treatment regimen of one or more agents, then begins a second treatment regimen of one or more different agents in addition to the first treatment regimen, such that not all agents used in the therapy are initiated simultaneously.

As used herein, "administering," "administering," and the like means administering, distributing, or administering a drug, medicine, or therapeutic agent to a subject (e.g., a mammalian subject, preferably a human) to alleviate or cure a pathological condition. Oral administration is a means of administering a compound of the invention to a subject.

As used herein, an "amount" or "dose" of a compound (e.g., AABZ) measured in milligrams refers to the number of milligrams of the compound present in the formulation, regardless of the form of the formulation. By "dose of 5.0 mg of the compound" is meant that the amount of the compound in the formulation is 5.0 mg, regardless of the form of the formulation. Thus, when in salt (e.g., hydrochloride salt) form, the weight of the salt form required to provide a 5.0 mg dose of the free base compound will be greater than 5.0 mg due to the presence of the additional acid.

As used herein, the term "5-ASA agent" means a compound containing a 5-aminosalicylic acid moiety. As used herein, unless otherwise indicated or apparent from the context, the term also includes salts or solvates of the compounds.

As used herein, "combination" means a collection of compounds for use in therapy by simultaneous or separate (e.g., sequential or concomitant) administration. Simultaneous administration refers to the administration of a mixture (whether a true mixture, suspension, emulsion, or other physical combination) of two active ingredients (e.g., AABZ and 5-ASA agents). In this case, the combination may be a mixture of AABZ and 5-ASA agent; alternatively, the AABZ and 5-ASA agents may be provided in separate containers and combined immediately prior to administration. Separate administration may be sequential (i.e., continuous) or concomitant (i.e., concurrent).

By separately administered is meant that the AABZ and 5-ASA agents are administered concomitantly or sequentially as separate formulations, but simultaneously or together in sufficiently close time proximity that at least additive activity is observed relative to the activity of either of the AABZ and 5-ASA agents alone.

As used herein, "CD" means crohn's disease.

As used herein, "Compound A (Cpd A)" means 4-acetamido-3-chloro-N- [2- (diethylamino) ethyl ] benzamide (N-acetyl chlorophenamine) hydrochloride.

As used herein, "DSS" means dextran sodium sulfate.

As used herein, when referring to the amount of AABZ or 5-ASA agent, "effective" refers to an amount sufficient to produce the desired therapeutic response without undue adverse side effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable benefit/risk ratio when used in the manner of this invention.

As used herein, an "excipient" is a substance formulated with a pharmaceutically active ingredient that is included for purposes such as: long term stability, providing bulk to the solid formulation, acting as a carrier and/or diluent, imparting a therapeutically enhancing effect (e.g., by promoting absorption, reducing viscosity, or enhancing solubility) to the active ingredient in the final dosage form. Excipients may also be used in the manufacturing process, for example, by promoting powder flowability or providing non-stick properties. Examples of excipients are antiadherents, binders, coatings, colorants, disintegrants, flavoring agents, glidants, lubricants, preservatives, adsorbents, sweeteners and vehicles (carriers).

As used herein, "a disease caused by pathological inflammation" refers to diseases such as inflammatory bowel disease, rheumatic diseases, autoimmune diseases and disorders, and further, such diseases in which inflammation plays a major role, such as alzheimer's disease, atherosclerosis, and stroke. More particularly, as used herein, "a disease caused by pathological inflammation" refers to a disease and disorder selected from ulcerative colitis, crohn's disease, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis, psoriasis, multiple sclerosis, and type I diabetes, and in particular, refers to a disease selected from ulcerative colitis and crohn's disease.

As used herein, "IBD" means inflammatory bowel disease.

As used herein, "inhibition" of disease progression or disease complication in a subject refers to preventing or reducing disease progression and/or disease complication in a subject.

As used herein, "nfkb" means nuclear factor kb.

As used herein, "I κ B" means an inhibitor of κ B.

As used herein, "pharmaceutically acceptable" means suitable for use in humans and/or animals, and is generally safe and non-toxic in normal use, i.e., without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.

As used herein, "SASP" means sulfasalazine.

As used herein, a "salt thereof" is a salt of a compound of the present invention that has been modified by making acid or base salts of the compound of the present invention. The term "pharmaceutically acceptable salts" refers in this respect to the relatively non-toxic, inorganic and organic acid or base addition salts of the compounds of the present invention. For example, one method of preparing such salts is to treat the compounds of the present invention with a mineral acid.

As used herein, "solvate" means a physical association, e.g., through hydrogen bonding, of a compound (e.g., a compound of formula (I)) with one or more solvent molecules. "solvates" encompasses both solution phase solvates and isolatable solvates. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Methods of solvation are generally known to those of ordinary skill in the art.

As used herein, "a subject having a disease caused by pathological inflammation" means a subject that has been clinically diagnosed as having such a disease.

As used herein, "symptoms" associated with a disease caused by pathological inflammation include any clinical or laboratory manifestations associated with the disease, and are not limited to symptoms that a subject may feel or observe.

As used herein, "TF" means a transcription factor.

As used herein, "TNF" means tumor necrosis factor.

As used herein, "TNF- α" means tumor necrosis factor α.

As used herein, "treating" encompasses, for example, inducing inhibition, regression, or stasis of a disease or disorder (e.g., IBD), or reducing, suppressing, inhibiting, reducing the severity of a disease or disorder, eliminating or substantially eliminating or ameliorating the symptoms of a disease or disorder.

As used herein, "UC" means ulcerative colitis.

IBD, including UC and CD, is a chronic, recurrent and remitting condition with no clear cure. Current drugs are moderately effective for inducing and maintaining clinical and endoscopic relief, and side effects are a problem. Thus, not all IBD patients respond adequately to currently available disease modifying drugs.

An important object of the present invention is to provide a new drug and method for the treatment of diseases caused by pathological inflammation (e.g. IBD), with the ultimate goal of altering the disease process. Without wishing to be bound by any theory, the inventors conclude that a more effective treatment of e.g. such diseases not only involves NF κ B inhibition, but also involves the use of NF κ B inhibitors in combination that exert a dual effect on NF κ B activity. By combining NF κ B inhibitors that together inhibit the degradation of both major forms of I κ B protein (i.e., I κ B α and I κ B β), therapies superior to existing therapies with 5-ASA alone may be achieved. The present inventors have unexpectedly and surprisingly found that combining a compound of formula (I) with more than a minimum effective amount of a 5-ASA agent as defined above, results in a synergistically enhanced therapeutic effect with advantageous safety profiles.

Thus, another aspect is AABZ for use in combination with a 5-ASA agent in the treatment of a disorder (a disease caused by pathological inflammation, such as IBD) that is associated with (e.g., mediated by) nfkb activity. Another aspect is AABZ for use in combination with a 5-ASA agent to inhibit nfkb activity in a mammalian (e.g., human) cell to treat a disorder (a disease caused by pathological inflammation, such as IBD) associated with (e.g., mediated by) nfkb activity. Another aspect is AABZ for use in combination with a 5-ASA agent to inhibit degradation of I κ B α and I κ B β in a cell to treat a disorder (a disease caused by pathological inflammation, such as IBD) associated with (e.g., mediated by) nfkb activity in a cell. Another aspect is a method for treating a disorder associated with (e.g., mediated by) nfkb activity (a disease caused by pathological inflammation, such as IBD) comprising administering to a mammal in need of such treatment a therapeutically effective amount of AABZ in combination with a therapeutically effective amount of a 5-ASA agent.

A compound of formula (I)

In the compounds of formula (I) as defined herein, R₁Selected from C1-C6 alkyl and C3-C6 cycloalkyl. In some embodiments, R₁Selected from C1-C5 alkylAnd C3-C5 cycloalkyl, for example selected from C1-C4 alkyl and C3-C4 cycloalkyl, or from C1-C3 alkyl and C3 cycloalkyl. In some embodiments, R₁Selected from C1-C6 alkyl, for example selected from C1-C5 alkyl or selected from C1-C4 alkyl or selected from C1-C3 alkyl, or selected from C1-C2 alkyl. In some embodiments, R₁Selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, cyclobutyl, n-pentyl, sec-pentyl, isopentyl, tert-pentyl, neopentyl and cyclopentyl; for example selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, sec-pentyl, isopentyl, tert-pentyl and neopentyl. In some embodiments, R₁Selected from methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl and cyclobutyl, for example selected from methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl. In some embodiments, R₁Selected from methyl, ethyl, n-propyl, isopropyl and cyclopropyl, for example selected from methyl, ethyl, n-propyl and isopropyl. In some embodiments, R₁Selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, sec-pentyl, isopentyl, tert-pentyl and neopentyl; for example selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl; or selected from methyl, ethyl, n-propyl and isopropyl; for example selected from methyl, ethyl and isopropyl. In some embodiments, R₁Is methyl or ethyl. In some embodiments, R₁Is methyl. In some embodiments, R₁Is ethyl. In some embodiments, R₁Is isopropyl.

The moiety R₂Selected from hydrogen and C1-C3 alkyl. In some embodiments, R₂Selected from hydrogen, methyl, ethyl, n-propyl and isopropyl; for example selected from hydrogen, methyl and ethyl; or selected from hydrogen and methyl. In some embodiments, R₂Is hydrogen.

The moiety R₃、R₄、R₅And R₆Independently selected from hydrogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, halogen, phenyl and benzyl, wherein any alkyl is optionally substituted with one or more fluoro.

In some embodiments, R₃、R₄、R₅And R₆Independently selected from hydrogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, and halogen, wherein any alkyl is optionally substituted with one or more fluoro. In some embodiments, R₃、R₄、R₅And R₆Independently selected from hydrogen, C1-C3 alkyl, C1-C3 alkoxy, and halogen, wherein any alkyl is optionally substituted with one or more fluoro. In still other embodiments, R₃、R₄、R₅And R₆Independently selected from hydrogen, C1-C3 alkyl, C1-C3 alkoxy, and halogen, wherein any alkyl is optionally substituted with one or more fluoro. In still other embodiments, R₃、R₄、R₅And R₆Independently selected from hydrogen, C1-C3 alkyl, and halogen, wherein any alkyl is optionally substituted with one or more fluoro. In still other embodiments, R₃、R₄、R₅And R₆Independently selected from hydrogen, C1-C3 alkoxy, and halogen, wherein any alkyl group is optionally substituted with one or more fluoro. In still other embodiments, R₃、R₄、R₅And R₆Independently selected from hydrogen, C1-C3 alkoxy, C1-C3 alkylthio, and halogen, wherein any alkyl is optionally substituted with one or more fluoro. In still other embodiments, R₃、R₄、R₅And R₆Independently selected from hydrogen and halogen.

When R is₃、R₄、R₅And R₆When any of them is selected from C1-C3 alkyl, it may be selected from methyl and ethyl, for example; in particular, it may be methyl.

When R is₃、R₄、R₅And R₆When any of them is selected from C1-C3 alkoxy, it may be selected from methoxy and ethoxy, for example; in particular, it may be methoxy.

When R is₃、R₄、R₅And R₆When any one of them is selected from C1-C3 alkylthio, it may be selected from methylthio and ethylthio, for example; in particular, it may be methylthio.

When R is₃、R₄、R₅And R₆When any of them is selected from halogen, said halogen may be selected from, for example, fluorine, chlorine and bromine; in particular, the halogen may be chlorine or bromine, for example chlorine. In some further embodiments, when R₃、R₄、R₅And R₆When any of them is selected from halogens, said halogens are more particularly selected from fluorine and chlorine.

In some embodiments, R₃、R₄、R₅And R₆Independently selected from hydrogen, methyl, ethyl, methoxy, ethoxy, methylthio, fluoro, chloro, bromo, trifluoromethyl, phenyl and benzyl, for example selected from hydrogen, methyl, ethyl, methoxy, ethoxy, methylthio, fluoro, chloro, bromo and trifluoromethyl; or selected from hydrogen, methyl, ethyl, methoxy, ethoxy, fluoro, chloro, bromo and trifluoromethyl; for example selected from hydrogen, methyl, methoxy, fluoro, chloro, bromo and trifluoromethyl; or selected from hydrogen, methyl, methoxy, chloro and trifluoromethyl, or selected from hydrogen, methyl, methoxy and chloro; or selected from hydrogen, methoxy and chlorine; or selected from hydrogen, methyl and chlorine; for example selected from hydrogen and chlorine.

In some of the above embodiments, R₃、R₄、R₅And R₆At least one, more preferably at least two of which are hydrogen. In some of the above embodiments, R₃、R₄、R₅And R₆Two of which are hydrogen. In some of the above embodiments, R₃、R₄、R₅And R₆Three of which are hydrogen. In some of the above embodiments, R₃、R₄、R₅And R₆Each of which is hydrogen. In some of the above embodiments, R₃、R₄、R₅And R₆At least one of which is different from hydrogen. In some of the above embodiments, R₃、R₄、R₅And R₆One of which is different from hydrogen and the other three are hydrogen; for example R₃、R₄、R₅And R₆Of (e.g. R)₃) Is halogen, such as chlorine; and the other three are hydrogen. In some of the above embodiments, R₃Is different from hydrogen, and R₄、R₅And R₆Each of which is hydrogen. In some embodiments, R₅Is different from hydrogen, and R₃、R₄And R₆Each of which is hydrogen. In some embodiments, R₃、R₄、R₅And R₆Of (e.g. R)₃) Fluorine, chlorine or bromine, in particular chlorine; and the other three are hydrogen. In some embodiments, R₃Hydrogen or halogen, hydrogen and chlorine; and R is₄、R₅And R₆Is hydrogen. In some embodiments, R₄And R₆Is hydrogen; for example R₄And R₆Is hydrogen, and R₃And R₅At least one of which is different from hydrogen, e.g. R₃And R₅Are all different from hydrogen. In some embodiments, R₄And R₅Is hydrogen; for example R₄And R₅Is hydrogen, and R₃And R₆At least one of which is different from hydrogen, e.g. R₃And R₆Are all different from hydrogen.

In some embodiments, R₃And R₄Is hydrogen; for example R₃And R₄Is hydrogen, and R₅And R₆At least one of which is different from hydrogen, e.g. R₅And R₆Are all different from hydrogen. In some of the above embodiments, R₅And R₆Not methoxy or ethoxy.

The moiety R₇Selected from hydrogen and C1-C3 alkyl. In some embodiments, R₇Selected from hydrogen, methyl, ethyl, propyl and isopropyl; for example selected from hydrogen, methyl, ethyl and propyl. In some embodiments, R₇Selected from hydrogen, methyl and ethyl. In some embodiments, R₇Selected from hydrogen and methyl. In some embodiments, R₇Is hydrogen.

The moiety R₈And R₉Independently selected from C1-C6 alkyl, or R₈And R₉Together with the nitrogen atom to which they are both attached form a moiety of formula (II) as defined herein. In some embodiments, R₈And R₉Independently selected from C1-C6 alkyl. When R is₈And R₉Selected from C1-C6 alkyl, R₈And R₉For example, it may be selected from C1-C5 alkyl groups; or selected from C1-C4 alkyl; or selected from C1-C3 alkyl; for example selected from methyl and ethyl. In some embodiments, when R₈And R₉Selected from C1-C6 alkyl, R₈And R₉Both are ethyl groups. In some embodiments, R₈And R₉Together with the nitrogen atom to which they are both attached form a moiety of formula (II) as defined herein, in which case the compound of formula (I) may be represented by formula (Ia)

Wherein R is₁-R₇、R₁₀Q, p and r are as defined herein.

In the moiety of formula (II), r is 0 or 1. In some embodiments, r is 0. In some embodiments, r is 1.

The moiety R₁₀Selected from C1-C3 alkyl and C3-C4 cycloalkyl; said alkyl and cycloalkyl groups being optionally substituted by hydroxy, halogen, cyano, COOR₁₂Or NHR₁₃And (4) substitution. In some embodiments, R₁₀Selected from methyl, ethyl and cyclopropyl optionally substituted by hydroxy, halogen, cyano, COOR₁₂Or NHR₁₃And (4) substitution. In some embodiments, R₁₀Selected from C1-C3 alkyl and C3-C4 cycloalkyl, optionally substituted with hydroxy, halogen and cyano; for example by halogen (e.g. fluorine). In some embodiments, R₁₀Selected from C1-C3 alkyl and C3-C4 cycloalkyl, such as methyl, ethyl and cyclopropyl, such as methyl.

The moiety Q is selected from CHR₁₁、NR₁₁And O. In some implementationsIn the scheme, Q is selected from CHR₁₁And NR₁₁. In some embodiments, Q is selected from CHR₁₁And O. In some embodiments, Q is CHR₁₁. In some other embodiments, Q is selected from NR₁₁And O.

The moiety R₁₁Selected from hydrogen, C1-C3 alkyl, and C3-C4 cycloalkyl; said alkyl and cycloalkyl groups being optionally substituted by hydroxy, halogen, cyano, COOR₁₂Or NHR₁₃And (4) substitution. In some embodiments, R₁₁Selected from hydrogen, methyl, ethyl and cyclopropyl, said methyl, ethyl and cyclopropyl being optionally substituted by hydroxy, halogen, cyano, COOR₁₂Or NHR₁₃And (4) substitution. In some embodiments, R₁₁Selected from hydrogen, C1-C3 alkyl and C3-C4 cycloalkyl, said alkyl and cycloalkyl being optionally substituted with hydroxy, halogen or cyano; for example by halogen, such as fluorine. In some embodiments, R₁₁Selected from hydrogen, C1-C3 alkyl and C3-C4 cycloalkyl, such as hydrogen, methyl, ethyl and cyclopropyl, or hydrogen, methyl and ethyl; especially hydrogen and methyl. In some embodiments, R₁₁Is hydrogen. In some other embodiments, R₁₁As defined above, but different from hydrogen.

When R is₁₁Is substituted by hydroxy, halogen, cyano, COOR₁₂Or NHR₁₃Substituted C1-C3 alkyl or C3-C4 cycloalkyl, the number of such substituents may be one or more, for example 1-3 or 1-2 or 1.

The moiety R₁₂Selected from hydrogen, C1-C3 alkyl and C3-C4 cycloalkyl. In some embodiments, R₁₂Selected from hydrogen, methyl, ethyl, n-propyl, isopropyl and cyclopropyl, for example selected from hydrogen, methyl, ethyl, n-propyl and isopropyl; or from hydrogen, methyl and ethyl, for example from hydrogen and methyl. In some embodiments, R₁₂Selected from hydrogen, C1-C3 alkyl and C3-C4 cycloalkyl. In some embodiments, R₁₂Selected from C1-C3 alkyl and C3-C4 cycloalkyl, for example selected from methyl, ethyl, n-propyl, isopropyl and cyclopropyl; selected from methyl, ethyl, n-propyl and isopropyl; or from methyl and ethyl, e.g. R₁₂Is methyl. At one endIn some other embodiments, R₁₂Is hydrogen.

The moiety R₁₃Selected from hydrogen, C1-C3 alkyl and C3-C4 cycloalkyl. In some embodiments, R₁₃Selected from hydrogen, methyl, ethyl, n-propyl, isopropyl and cyclopropyl, for example selected from hydrogen, methyl, ethyl, n-propyl and isopropyl; or from hydrogen, methyl and ethyl, for example from hydrogen and methyl. In some embodiments, R₁₃Selected from hydrogen, C1-C3 alkyl and C3-C4 cycloalkyl. In some embodiments, R₁₃Selected from C1-C3 alkyl and C3-C4 cycloalkyl, for example selected from methyl, ethyl, n-propyl, isopropyl and cyclopropyl; selected from methyl, ethyl, n-propyl and isopropyl; or from methyl and ethyl, e.g. R₁₃Is methyl. In some other embodiments, R₁₃Is hydrogen.

In the moiety of formula (II), when Q is CHR₁₁When p is 1,2 or 3; and when Q is selected from NR₁₁And when O, p is 2 or 3. In some embodiments, p is 2 or 3. In some embodiments, p is 2. In some embodiments, Q is CHR₁₁And p is 1 or 2. In some embodiments, Q is CHR₁₁And p is 2. In some other embodiments, Q is CHR₁₁And p is 1.

In some embodiments of the compounds of formula (I), R₁Is C1-C6 alkyl; r₂Is hydrogen; r₇Is hydrogen; r₈And R₉Independently selected from C1-C6 alkyl, or R₈And R₉Together with the nitrogen atom to which they are both attached form a moiety of formula (II) as defined herein; r₁₀Is C1-C3 alkyl; q is CHR₁₁(ii) a And R is₁₁Selected from hydrogen and C1-C3 alkyl.

In some embodiments, R₁Is C1-C6 alkyl; r₂Is hydrogen; r₇Is hydrogen; and R is₈And R₉Independently selected from C1-C6 alkyl. In some of these embodiments, R₁、R₈And R₉Independently selected from C1-C3 alkyl.

In some further embodiments, R₁Is C1-C3 alkyl; r₂、R₄、R₅And R₇Is hydrogen; and R is₈And R₉Independently selected from C1-C3 alkyl. In some of these embodiments, R₁Selected from methyl, ethyl and isopropyl; and R is₈And R₉Identical or different and selected from methyl, ethyl and n-propyl.

In some further embodiments, R₁Selected from methyl, ethyl and isopropyl; r₂、R₄、R₅、R₆And R₇Is hydrogen; and R is₈And R₉Identical or different and selected from methyl, ethyl and n-propyl.

In some embodiments, R₂Selected from hydrogen and methyl; r₃、R₄、R₅And R₆Independently selected from hydrogen and chlorine; r₇Is hydrogen; and R is₈And R₉Identical or different and selected from methyl, ethyl and n-propyl.

In some embodiments, R₁Selected from methyl, ethyl and isopropyl; r₂Is hydrogen or methyl; r₃Is chlorine or hydrogen; r₄、R₅、R₆And R₇Is hydrogen; and R is₈And R₉Identical or different and selected from methyl, ethyl and n-propyl. In some further embodiments, R₁Selected from methyl, ethyl and isopropyl; r₂Is hydrogen or methyl; r₃Is chlorine or hydrogen; r₄、R₅、R₆And R₇Is hydrogen; and R is₈And R₉Is ethyl. In some other embodiments, R₁Selected from methyl, ethyl and isopropyl; r₂Is hydrogen; r₃Is chlorine or hydrogen; r₄、R₅、R₆And R₇Is hydrogen; and R is₈And R₉Identical or different and selected from methyl, ethyl and n-propyl.

In some embodiments, R₁Selected from methyl, ethyl and isopropyl; r₂Is hydrogen; r₃Is chlorine; r₄、R₅、R₆And R₇Is hydrogen; and R is₈And R₉The same or differentAnd is selected from methyl, ethyl and n-propyl.

In some embodiments, the compound of formula (I) is selected from:

4-acetylamino-3-chloro-N- [2- (diethylamino) ethyl ] benzamide,

4-propionylamino-3-chloro-N- [2- (diethylamino) ethyl ] benzamide,

4-isobutyramido-3-chloro-N- [2- (diethylamino) ethyl ] benzamide,

4-acetylamino-N- [2- (diethylamino) ethyl ] benzamide,

n- [2- (diethylamino) ethyl ] -4- (propionylamino) benzamide, and

n- [2- (diethylamino) ethyl ] -4- (isobutyramido) benzamide.

In some embodiments, the compound of formula (I) is selected from

4-acetylamino-3-chloro-N- [2- (diethylamino) ethyl ] benzamide,

4-propionylamino-3-chloro-N- [2- (diethylamino) ethyl ] benzamide,

4-isobutyrylamino-3-chloro-N- [2- (diethylamino) ethyl ] benzamide, and

4-acetylamino-N- [2- (diethylamino) ethyl ] benzamide.

In some embodiments, the compound of formula (I) is 4-acetamido-3-chloro-N- [2- (diethylamino) ethyl ] benzamide. In some embodiments, the compound of formula (I) is 4-propionylamino-3-chloro-N- [2- (diethylamino) ethyl ] benzamide. In some embodiments, the compound of formula (I) is 4-isobutyrylamino-3-chloro-N- [2- (diethylamino) ethyl ] benzamide. In some embodiments, the compound of formula (I) is 4-acetamido-N- [2- (diethylamino) ethyl ] benzamide. In some embodiments, the compound of formula (I) is N- [2- (diethylamino) ethyl ] -4- (propionylamino) benzamide. In some embodiments, the compound of formula (I) is N- [2- (diethylamino) ethyl ] -4- (isobutyramido) benzamide.

In some embodiments, AABZ is the hydrochloride salt of the compound of formula (I), e.g., any of the above-listed hydrochloride salts of the compound of formula (I), e.g., AABZ is

4-acetylamino-3-chloro-N- [2- (diethylamino) ethyl ] benzamide hydrochloride.

The structural formulae of some of the compounds mentioned herein are shown in table 1.

TABLE 1

4-acetylamino-3-chloro-N- [2- (diethylamino) ethyl group]Benzamide derivatives
		4-propionylamino-3-chloro-N- [2- (diethylamino) ethyl group]Benzamide derivatives
4-isobutyrylamino-3-chloro-N- [2- (diethylamino) ethyl group]Benzamide derivatives
		4-acetylamino-N- [2- (diethylamino) ethyl group]Benzamide derivatives
4-propionylamino-N- [2- (diethylamino) ethyl]Benzamide derivatives
		4-isobutyrylamino-N- [2- (diethylamino) ethyl]Benzamide derivatives

Process for the preparation of a compound of formula (I)

The compounds of formula (I) can be readily prepared by one of ordinary skill in the art, for example, by following the general procedures as disclosed in U.S. patent application No. 2011/0027179 and WO 2005/025498. For example, the compounds of formula (I) may be prepared by a process comprising two sequential nucleophilic substitution reactions, as shown in the following reaction scheme.

In the above reaction scheme, Compound 1 (wherein R is_aE.g., C1-C3 alkyl) with compound 2 (wherein L is a suitable leaving group, e.g., Cl) to afford compound 3. Compound 3 is subsequently reacted with a secondary amine 4 in the presence of ammonium chloride as reaction catalyst to obtain a compound of formula (I) as defined herein. The compounds of formula (I) may optionally be converted into suitable pharmaceutically acceptable salts or solvates, for example, the hydrochloride salt.

5-ASA agents

Examples of 5-ASA agents according to the invention are mesalamine, sulfasalazine, olsalazine or balsalazide (which may also be referred to as balsalazine) or a pharmaceutically acceptable salt thereof. In Table 2, the structural formulas of some of the 5-ASA agents are shown.

TABLE 2

5-ASA agents	Structural formula (I)
		Mesalazine
Sulfasalazine
		Oxalazine
Balsalazide

In some embodiments, the 5-ASA agent is mesalamine, sulfasalazine, olsalazine, or balsalazide, or a pharmaceutically acceptable salt or solvate of any of these compounds. However, it should be noted that the present invention is not limited to these compounds. Rather, any 5-ASA prodrug or formulation capable of releasing 5-ASA or a salt or solvate thereof in vivo is contemplated as being useful in accordance with the present invention.

In some embodiments, the 5-ASA agent is mesalamine or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the 5-ASA agent is sulfasalazine or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the 5-ASA agent is oxalazine or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the 5-ASA agent is balsalazide or a pharmaceutically acceptable salt or solvate thereof.

In some embodiments, the 5-ASA agent is a colon-specific prodrug of 5-ASA designed to achieve colonic delivery. Such prodrugs comprise a carrier moiety linked to 5-ASA through the carboxyl or hydroxyl functionality of the 5-ASA. As colon-specific prodrugs of 5-ASA, esters and amides have been reported (Amidon, 2015), and any such prodrug is contemplated for use herein.

In particular, Amidon et al (2015) describe on page 731 the criteria for colon-specific drug delivery. In some embodiments, the 5-ASA agent is a colon-specific prodrug that meets this criteria for colon-specific delivery.

Additional examples of 5-ASA prodrugs useful herein are disclosed, for example, in U.S. patent No. 7,157,444 and Jung (1998) and Jung (2003); such as 5-aminosalicyl-glycine and 5-aminosalicyl-taurine.

In some embodiments, the 5-ASA agent is a formulation capable of releasing 5-ASA or a salt or solvate thereof, or capable of releasing a 5-ASA prodrug, in vivo (e.g., in the colon). In some embodiments, the 5-ASA agent is a formulation capable of delayed release of 5-ASA or a salt thereof (e.g., hydrochloride salt) in the colon.

Pharmaceutically acceptableAcceptable salts

AABZ may be provided in the form of a pharmaceutically acceptable salt (e.g., an acid addition salt) of a compound of formula (I). Likewise, the 5-ASA agent may be provided in the form of a pharmaceutically acceptable salt (e.g. a base addition salt). In the preparation of acid or base addition salts, it is preferred to use acids or bases which form suitable therapeutically acceptable salts. Examples of such acids are hydrohalic acids, sulfuric acid, phosphoric acid, nitric acid, aliphatic, cycloaliphatic, aromatic or heterocyclic carboxylic or sulfonic acids, for example formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, pyruvic acid, p-hydroxybenzoic acid, pamoic acid, methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid, halobenzenesulfonic acid, toluenesulfonic acid or naphthalenesulfonic acid. Base addition salts include those derived from inorganic bases such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like, and those derived from organic bases such as alkoxides, alkylamides, alkyl and arylamines, and the like. Examples of bases useful in preparing the salts of the present invention include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, and the like.

In some embodiments, the compound of formula (I) is provided as a hydrochloride salt. In some embodiments, the 5-ASA agent is provided as a salt of a strong base (e.g., an alkali metal salt, such as a sodium salt).

Relevant teachings regarding salt formulations used herein and methods of making the same are described, for example, in U.S. patent No. 3,177,252, and such teachings are incorporated herein by reference.

Pharmaceutically acceptable solvates

It is contemplated that any pharmaceutically acceptable solvate is possible according to the present invention. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. In some embodiments, the solvate is a hydrate.

Combined use of AABZ and 5-ASA agents

One aspect is a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof (AABZ) as defined herein, for use in combination with a 5-ASA agent in the treatment of a disease caused by pathological inflammation.

In some embodiments, the treatment comprises administering to a subject (a mammalian patient, e.g., a human patient) an amount of AABZ and greater than a minimum effective amount of 5-ASA agent, wherein the amounts when taken together are effective to treat the subject. In some embodiments, when AABZ and 5-ASA agent are administered together to treat a subject, the total amount of AABZ and 5-ASA agent produces an overall better effect, i.e., a synergistic effect, than a simple addition of the effects produced by either component administered alone in the same total amount.

In some embodiments, the treatment comprises administering AABZ to a subject (a mammalian patient, e.g., a human patient) as an add-on therapy or in combination with a 5-ASA agent in treating a subject having pathological inflammation, IBD (e.g., UC or CD). Preferably, the treatment provides induction and maintenance of clinical and endoscopic remission in patients with mild to moderate to severe disease activity. In some embodiments, the treatment is intended for patients in remission to prevent disease recurrence.

In some embodiments, AABZ is a pharmaceutically acceptable salt, particularly the hydrochloride salt, of the compound of formula (I).

In some embodiments, AABZ is administered orally. In some embodiments, AABZ is administered in a preferably solid unit formulation, more preferably a tablet.

In some embodiments, the amount of AABZ administered is from 0.1 to 25 mg/kg (mg of drug per kg of subject body weight) per day (any weight value is based on the non-salt, non-solvate form). In other embodiments, the amount of AABZ administered is from 0.3 to 10 mg/kg per day.

In some embodiments, the amount of AABZ administered is 5.0-2000 mg/day, or 10-1000 mg/day.

In some embodiments, AABZ is administered daily, e.g., once daily. In other embodiments, AABZ is administered twice daily. In other embodiments, AABZ is administered three times per day. In yet other embodiments, AABZ is administered four times per day.

In some embodiments, the 5-ASA agent is administered by oral administration. In yet other embodiments, the 5-ASA agent is administered by rectal administration.

In some embodiments, the 5-ASA agent is administered daily. In some embodiments, the 5-ASA agent is administered in an amount of from 250 mg/day to 8000 mg/day (any weight value is based on the non-salt, non-solvate form). In some embodiments, the 5-ASA agent is administered in an amount of less than 8000 mg/day. In other embodiments, the 5-ASA agent is administered in an amount of less than 6750 mg/day. In other embodiments, the 5-ASA agent is administered in an amount of less than 4000 mg/day. In other embodiments, the 5-ASA agent is administered in an amount of less than 2000 mg/day.

In some embodiments, the 5-ASA agent is administered once daily. In other embodiments, the 5-ASA agent is administered twice daily. In other embodiments, the 5-ASA agent is administered three times per day. In yet other embodiments, the 5-ASA agent is administered four times per day.

The amount of AABZ and the amount of 5-ASA agent, when taken together, are preferably effective to reduce symptoms of pathological inflammation (e.g., IBD) in the subject. Symptoms vary according to the severity of the inflammation and can vary from mild to severe. Signs and symptoms common to both CD and UC include diarrhea and urgency, fever and fatigue, abdominal pain and cramps, hematochezia, and reduced appetite. The symptoms of autoimmune diseases vary with the disease.

In some embodiments, the administration of the 5-ASA agent is significantly prior to the administration of the AABZ, i.e., the subject receives treatment by administration of the 5-ASA agent prior to beginning treatment by administration of the AABZ.

In some embodiments, the subject receives treatment by administration of a 5-ASA agent for at least 6 months prior to initiation of treatment by administration of AABZ. In some embodiments, the subject receives treatment by administration of a 5-ASA agent for at least 12 months prior to initiation of treatment by administration of AABZ. In some embodiments, the subject receives treatment by administration of a 5-ASA agent for at least 24 months prior to initiation of treatment by administration of AABZ.

In some embodiments, the treatment comprises administration of at least one additional agent, for example selected from the group consisting of a non-steroidal anti-inflammatory drug (NSAID), a corticosteroid, a cytotoxic drug, an immunosuppressive drug, and an antibody.

In some embodiments, the AABZ and 5-ASA agent are administered for at least 2 weeks. In other embodiments, the AABZ and 5-ASA agents are administered for 3 months or more. In yet other embodiments, the AABZ and 5-ASA agents are administered for 12 months or more.

In some embodiments, the AABZ and 5-ASA agents are administered in combination (simultaneously, or separately and concomitantly or sequentially) with each other in a molar ratio of AABZ to 5-ASA of from 1:100 to 100:1, such as from 1:50 to 50:1, or from 1:20 to 20:1, or from 1:10 to 10:1, or from 1:5 to 5:1, or from 1:2 to 2:1, such as about 1: 1.

In some embodiments, 4-acetamido-3-chloro-N- [2- (diethylamino) ethyl ] benzamide, or a pharmaceutically acceptable salt thereof (e.g., the hydrochloride salt), and sulfasalazine, or a pharmaceutically acceptable salt thereof (e.g., the sodium salt), are administered in combination with each other.

AABZ can be administered in admixture with a suitable pharmaceutical diluent, extender or carrier, or any other pharmaceutically acceptable excipient suitably selected in accordance with the intended form of administration and in accordance with conventional pharmaceutical practice. Preferred dosage units will be in a form suitable for oral administration. AABZ can be administered alone, but is typically mixed with a pharmaceutically acceptable carrier and co-administered in the form of tablets or capsules, liposomes, or as an agglomerated powder. Examples of suitable solid carriers include lactose, sucrose, gelatin, and agar. Capsules or tablets can be easily formulated and can be manufactured to be easily swallowed or chewed; other solid forms include granules and bulk powders.

Tablets may contain suitable binders, lubricants, disintegrating agents, coloring agents, flavoring agents, flow inducing agents and melting agents. For example, for oral administration in the form of a dosage unit of a tablet or capsule, the active pharmaceutical ingredient may be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, gelatin, agar, starch, sucrose, glucose, methyl cellulose, dicalcium phosphate, calcium sulfate, mannitol, sorbitol, microcrystalline cellulose and the like. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn starch, natural and synthetic gums such as acacia, tragacanth or sodium alginate, povidone, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, sodium benzoate, sodium acetate, sodium chloride, stearic acid, sodium stearyl fumarate, talc and the like. Disintegrants include, but are not limited to, starch, methylcellulose, agar, bentonite, xanthan gum, croscarmellose sodium, sodium starch glycolate, and the like.

Another aspect is AABZ for use as an add-on therapy or in combination with a 5-ASA agent for treating a subject having pathological inflammation (e.g., IBD).

Another aspect is a 5-ASA agent for use in treating a subject having pathological inflammation (e.g., IBD) by administering the 5-ASA agent and AABZ to the subject.

Subject of treatment

The subject treated according to the invention is a mammal, including human and non-human mammals (animals). Examples of non-human mammals are primates, domestic animals, e.g., livestock, such as cattle, sheep, pigs, horses, etc., and pet animals, such as dogs and cats, etc. In a preferred embodiment, the subject is a human. In some other embodiments, the subject is a non-human mammal, such as a dog or horse.

Disease and disorder

The disease to be treated according to the invention is a disease caused by pathological inflammation as defined herein. In some embodiments, the disease is IBD. In some embodiments, the disease is UC. In some embodiments, the disease is CD. As mentioned above, CD may affect any part of the gastrointestinal tract. In some embodiments, the CD affects the colon.

Multi-component kit

One aspect is a kit of parts comprising a combination of AABZ and 5-ASA agent, wherein each of the components AABZ and 5-ASA agent is optionally formulated in admixture with a pharmaceutically acceptable excipient (e.g., a carrier). In some embodiments, a kit of parts (e.g., for treating IBD) is provided, comprising: a) a first pharmaceutical composition comprising an amount of AABZ and a pharmaceutically acceptable carrier; b) a second pharmaceutical composition comprising an amount of a 5-ASA agent and a pharmaceutically acceptable carrier; and c) instructions for using the first pharmaceutical composition and the second pharmaceutical composition together.

Pharmaceutical composition

One aspect is a pharmaceutical composition comprising an amount of AABZ, an amount of a 5-ASA agent, and optionally (but preferably) at least one pharmaceutically acceptable excipient (e.g., carrier). In some embodiments, the pharmaceutical composition is for treating a subject having IBD.

Typically, suitable pharmaceutical compositions are those described above in connection with the pharmaceutical formulation of AABZ, but which contain, in addition to AABZ, a 5-ASA agent.

In some embodiments, AABZ is a pharmaceutically acceptable salt, e.g., hydrochloride salt, of the compound of formula (I).

In some embodiments, the amount of AABZ in the composition is 5-500 mg (any amount based on the compound of formula (I) in non-salt and non-solvate forms). In other embodiments, the amount of AABZ is 10-100 mg. In other embodiments, the amount of AABZ is 5-25 mg. In one embodiment, the amount of AABZ in the composition is 500 mg. In other embodiments, the amount of AABZ is 25 mg. In other embodiments, the amount of AABZ is 100 mg. In other embodiments, the amount of AABZ is 10 mg. In other embodiments, the amount of AABZ is less than 10 mg.

In some embodiments, the amount of 5-ASA agent in the composition is 225-1200 mg (any amount based on the non-salt and non-solvate forms of the compound of formula (I)). In other embodiments, the amount of 5-ASA agent is 500-1000 mg. In other embodiments, the amount of 5-ASA agent is 225-450 mg. In one embodiment, the amount of 5-ASA agent in the composition is 750 mg.

In some embodiments, the molar ratio of AABZ to 5-ASA in the pharmaceutical composition is from 1:100 to 100:1, such as from 1:50 to 50:1, or from 1:20 to 20:1, or from 1:10 to 10:1, or from 1:5 to 5:1, or from 1:2 to 2:1, for example the molar ratio may be about 1: 1.

In some embodiments, the total amount of AABZ and 5-ASA agent is from 0.1% to 95%, such as from 0.5% to 50%, or from 1% to 20%, by weight of the formulation, with the remainder comprising, for example, carriers and any other excipients.

In some embodiments, the pharmaceutical composition comprises 4-acetamido-3-chloro-N- [2- (diethylamino) ethyl ] benzamide, or a pharmaceutically acceptable salt thereof (e.g., the hydrochloride salt), and sulfasalazine, or a pharmaceutically acceptable salt thereof (e.g., the sodium salt).

Specific examples of techniques, pharmaceutically acceptable carriers and excipients that may be used to formulate oral dosage forms of the invention are described in, for example, EP 1720531B 1. General techniques and compositions for making dosage forms useful in the present invention are described in the following references: modern pharmaceuticals, chapters 9 and 10 (Banker and Rhodes editions, 1979); pharmaceutical Dosage Forms, Tablets (Lieberman et al, 1981); ansel, Introduction to Pharmaceutical Dosage Forms, 2 nd edition (1976); remington's Pharmaceutical Sciences, 17 th edition (Mack Publishing Company, Easton, Pa., 1985) (and later); advances in Pharmaceutical Sciences (David Ganderton, Trevor Jones eds., 1992); advances in Pharmaceutical Sciences, Vol.7 (David Ganderton, Trevor Jones, James McGinity, 1995); aqueous Polymeric Coatings for Pharmaceutical Dosage Forms (Drugs and the Pharmaceutical Sciences, series 36(James McGinity eds., 1989); Pharmaceutical Particulate Carriers: Therapeutic Applications: Drugs and the Pharmaceutical Sciences, Vol.61 (Alain Rolland eds., 1993); Drug Delivery to the Pharmaceutical specific track (Ellis Horwood Books in the Biological Sciences. Sequences in Pharmaceutical Technology; J.G.Hardy, S.S. Davis, Clive G. Wilson, eds.; and model Drugs Pharmaceutical Dosage Forms, Vol.40, incorporated by reference in their entirety by the present application, T.40.

The following examples are intended to illustrate the invention without limiting its scope.

Examples

Intermediate 1

4-acetylamino-3-chlorobenzoic acid ethyl ester

Ethyl 4-amino-3-chlorobenzoate (2.0 g, 10 mmol) and 1.4 g triethylamine were dissolved in 20 mL dichloromethane. 0.9 g of acetyl chloride in 5 mL of dichloromethane are added dropwise at 0 ℃. The reaction mixture was allowed to reach room temperature, stirred for 3 hours, washed with water, and dried. Evaporation of the solvent gave 2.0 g of the title product.

Example 1

4-acetylamino-3-chloro-N- [2- (diethylamino) ethyl group]Benzamide hydrochloride

1.5 g of ethyl 4-acetylamino-3-chlorobenzoate (1.5 g, 6.2 mmol) were dissolved in 15 mL of N ', N' -diethylethane-1, 2-diamine together with a catalytic amount of ammonium chloride. The reaction mixture was refluxed for 3 hours. Dichloromethane was added and washed 4 times with water to remove excess diamine. Drying and evaporation of the solvent gave the free base of the title compound. The residue was dissolved in ethanol-ether and acidified with ethanolic hydrogen chloride solution. The precipitated solid was collected to give the title compound (1.1 g, 3.1 mmol, 50% yield).

1H NMR (DMSO-d6): δ 1,23 (t, 6H), 2,15 (s, 3H), 3,17-3,23 (6H), 3,65 (q, 2H), 7,88 (d, 1H), 7,94 (s, 1H), 8,06 (s, 1H), 9,05 (t, 1H), 9,68 (s, 1H), 10,42 (s, 1H)。

Example 2

4-propionylamino-3-chloro-N- [2- (diethylamino) ethyl group]Benzamide hydrochloride

4-amino-N- [2- (diethylamino) ethyl ] benzamide hydrochloride (0.5 g, 1.6 mmol), pyridine (5.0 mL) and propionic anhydride (5.0 mL) were stirred at 50 ℃ for 2.5 h. Volatiles were then removed using a rotary evaporator. Water (5 mL) was added and evaporated. The residue was lyophilized from water and the title compound was obtained (0.6 g, 100% yield, HPLC purity 98%).

1H NMR (400 MHz, methanol-d 4) δ 8.07 (d, J = 8.6 Hz, 1H), 8.01 (d, J = 2.0 Hz, 1H), 7.83 (dd, J = 8.6, 2.0 Hz, 1H), 3.76 (t, J = 6.2 Hz, 2H), 3.39 (t, J = 6.2 Hz, 2H), 3.34 (q, J = 7.3 Hz, 4H), 2.52 (q, J = 7.6 Hz, 2H), 1.36 (t, J = 7.3 Hz, 6H), 1.23 (t, J = 7.6 Hz, 3H).

Example 3

4-isobutyrylamino-3-chloro-N- [2- (diethylamino) ethyl group]Benzamide hydrochloride

The compound 4-isobutyrylamino-3-chloro-N- [2- (diethylamino) ethyl ] benzamide hydrochloride was obtained in substantially the same manner by using isobutyric anhydride instead of propionic anhydride. According to HPLC, the purity was 99%.

1H NMR (400 Mhz, methanol-d 4) δ 8.01 (d, J = 2.2 Hz, 1H), 8.00 (d, J = 8.5 Hz, 1H), 7.83 (dd, J = 8.5, 2.0 Hz, 1H), 3.76 (t, J = 6.2 Hz, 2H), 3.39 (t, J = 6.2 Hz, 2H), 3.34 (q, J = 7.3 Hz, 4H), 2.80 (heptad, J = 6.8 Hz, 1H), 1.36 (t, J = 7.3 Hz, 6H), 1.24 (d, J = 6.9 Hz, 6H).

Example 4

4-acetylamino-N- [2- (diethylamino) ethyl group]Benzamide hydrochloride

The suspension of 4-amino-N- [2- (diethylamino) ethyl ] benzamide hydrochloride (2.5 g, 9.1 mmol) was stirred in 20 mL of anhydrous pyridine. To the suspension was added 10 mL of acetic anhydride. The reaction was slightly exothermic. After 1h, the precipitate was filtered off, washed with ethyl acetate, and dried to provide the title compound (2.83 g, 9.0 mmol, 99% yield). According to NMR, the purity was 98%.

1H NMR (400 Mhz, methanol-d 4), delta 7.84 (d, 2H), 7.68 (d, 2H), 3.74 (t, 2H), 3.37 (t, 2H), 3.35-3.29 (m, 4H), 2.14 (s, 3H), 1.35 (t, 6H).

Biological assay

UC is an inflammatory disease characterized by infiltration of inflammatory cells (e.g., macrophages) into the diseased colon. Macrophages play a key role in the initiation and spread of inflammatory responses by releasing proinflammatory mediators (e.g., TNF- α). Lipopolysaccharide (LPS) is a potent initiator of inflammatory reactions. During stimulation with LPS, NF-. kappa.B signaling is activated to regulate transcription of many genes involved in immunity and inflammation, producing proinflammatory cytokines, such as TNF-. alpha.. Inhibition of LPS-induced TNF- α production in RAW264.7 macrophages treated with AABZ was investigated by assessing TNF- α production. The aim of this study was to evaluate the anti-inflammatory activity of AABZ.

Both Dextran Sodium Sulfate (DSS) and trinitrobenzenesulfonic acid (TNBS) -induced colitis are established animal models of mucosal inflammation that have been used for more than twenty years in studies of IBD pathogenesis and preclinical studies of new therapies. DSS-induced colitis models have some advantages when compared to other colitis animal models (Perse, 2012) and are therefore selected for analysis of combination therapy effects.

Example 5

Inhibition of LPS-induced TNF- α production in macrophages treated with AABZ.

RAW264.7 macrophage line was maintained in DMEM supplemented with 5% FBS at 37 ℃ in 5% CO₂In a humidified air environment. RAW264.7 cells were plated at 1X 10⁵The density of the/ml and the volume of 200. mu.l/well were seeded in 96-well plates. Cells were incubated in medium supplemented with 10% FBS for 24 hours, then pre-incubated with or without the indicated concentrations of test substance for 2 hours, before addition of LPS (1 μ g/ml). Supernatants were then harvested at various time points and assayed for the production of the pro-inflammatory cytokine TNF-. alpha.in culture media using a commercially available enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's protocol.

The effect of 1 mM of some AABZ of the invention on LPS-induced TNF-production in RAW264.7 murine macrophages is shown in table 3.

TABLE 3.1 mM AABZ Effect on LPS-induced TNF-production in RAW264.7 murine macrophages

Compound (I)	Inhibition of TNF production%
		Control of LPS treatment	0
4-acetylamino-3-chloro-N- [2- (diethylamino) ethyl group]Benzamide hydrochloride	45
		4-propionylamino-3-chloro-N- [2- (diethylamino) ethyl group]Benzamide hydrochloride	50
4-isobutyrylamino-3-chloro-N- [2- (diethylamino) ethyl group]Benzamide hydrochloride	63
		4-acetylamino-N- [2- (diethylamino) ethyl group]Benzamide hydrochloride	56

Compound a.

It was observed that different concentrations (0.3 mM, 1.0 mM and 3.0 mM) of the compound significantly reduced the expression level of TNF compared to the LPS-treated control group. These results support the usefulness of the compounds as disclosed herein for the treatment of diseases caused by pathological inflammation.

Example 6

Evaluation of Compound A alone or in combination with SASP in Dextran Sodium Sulfate (DSS) -induced inflammatory bowel The effects in the disease

After a one-week acclimation period, experiments were performed with 6-8 week-old female Balb/c mice. Mice weighing 18-25 g were purchased from Taconic (denmark) and maintained in a temperature and light controlled facility, allowing free access to standard rodent chow and water. Mice were randomized into groups five days prior to initiation of treatment and kept for 5 to 6 animals per cage. After the adaptation period, acute colitis was induced by drinking water administration of a 5% DSS solution (DSS from TdBConsultaryAB, sweden; MW-40000) for five days (day 0 to day 5), which resulted in reproducible colitis characterized by diarrhea, rectal bleeding, weight loss, mucosal ulceration, crypt destruction and leukocyte infiltration. DSS intake was assessed daily.

SASP (from Sigma-Aldrich, Sweden) was first dissolved in 0.2M sodium hydroxide (NaOH) at a concentration higher than the desired final concentration. Phosphate Buffered Saline (PBS) was added to reach the desired concentration and the pH was adjusted to 7.5-8.0 with NaOH or hydrochloric acid. At this pH, the SASP remained completely dissolved. Compound a hydrochloride was dissolved in PBS to the desired concentration.

All groups of animals had free access to 5% DSS in water throughout the entire experiment. From day 0 to day 5, the therapeutic agent was administered orally (SASP) or intraperitoneally (compound a) by gavage at a volume of 5 ml/kg twice daily, approximately 8 hours apart. The control group (DSS only) received water (0.2 ml) orally twice daily. Parameters recorded in the experiment were stool consistency (0, normal; 2, loose stools; 4, watery diarrhea), appearance of blood in the stools (0, normal; 2, occult +; 4, severe bleeding), and weight loss (0, none; 1, 1-5%, 2, 5-10%, 3, 10-20%, 4, > 20%). The Disease Activity Index (DAI) was calculated by summarizing the scores of these three parameters. Colon length and colon content of Myeloperoxidase (MPO) were also recorded. Data were statistically evaluated using analysis of variance (ANOVA). The least squares means (LS mean) and the Standard Error (SE) of the LS mean are calculated.

Table 4 shows the percent inhibition of the effect of dextran sodium sulfate recorded on day 5 (100% = full normalization, 0% = no effect).

TABLE 4 The% inhibition of disease Activity index of sodium dextran sulfate on day 5 relative to control

(100% = complete normalization, 0% = no effect).

Administration of 5% DSS for 5 days resulted in severe acute colitis with diarrhea, hematochezia and weight loss. Diarrhea and hematochezia appeared from day 3 and these symptoms worsened until the end of the study on day 5. Oral treatment with SASP (40 mg/kg/day, twice daily was found to be the optimal dose) ameliorated some of these manifestations of colitis. From day 3 onwards, diarrhea and hematochezia improved. On day 3, the frequency of diarrhea (fecal consistency scores of 2 and 4) was 22% in the control group and 8% in the SASP 40 mg/kg/day two times a day group. On day 5, the corresponding numbers are 98% and 71%, respectively. The combination of compound a (50 mg/kg/day, twice daily) with SASP (20 mg/kg/day, twice daily) resulted in excellent improvement of colitis parameters (table 4). Compound a in combination with SASP was synergistic in ameliorating DSS-induced acute colitis (p < 0.008). Combination treatment significantly reduced Disease Activity Index (DAI) score by 51% (p < 0.0001) compared to control group, and by 47% (p < 0.0002) compared to SASP (20 mg/kg/day, twice daily) alone group.

Reference to the literature

Amidon S et al AAPS PharmSciTech. 201516: 731-41.

Azad Khan AK et al Lancet 1977310: 892-5.

Hanauer SB. Aliment PharmacolTher 2004 20:60-65.

Harrington RA et al Drugs 198325: 451-94.

Harron DWG et al, Drugs 199039: 720-.

Ivanenkov YA et al Mini Rev Med chem.20111: 55-78.

Jung YJ et al, Arch Pharm Res. 199821: 174-8.

Jung YJ et al, Arch Pharm Res. 200326: 264-9.

Kaiser GC et al gastroenterology 1999116: 602-9.

Kim W et al Mol pharm. 201613: 2126-35.

Liberg D et al Br J cancer. 199981: 981-8.

Lim WC et al Cochrane Database Syst Rev.20167: CD008870.

Lindgren H et al Mol Immunol 200138: 267-77.

Lindgren H et al biochem Biophys Res Commun. 2003301: 204-11.

MacDermott RP. Am J Gastroenterol. 2000 95:3343-5.

Mills S et al, Clin Colon recovery surg. 200720: 309-.

Peppercorn MA et al J Pharmacol Exp ther 1972181: 555-62.

Pero RW et al, Cancer Detect Prev. 199822: 225-.

Pero RW et al mol. cell. biochem. 1999193: 119-125.

Per š e M et al J Biomed Biotechnol. 20122012: 718617.

Rang HP et al Br J Anaesth. 199575: 145-56.

Stanley M et al 1982 The Benzamides: Pharmacology, Neurobiology and Clinical applications, Raven Press: New York.

Svartz N. Acta Medica Scandinavica. 1942 110:577-598.

Thompson JE et al, cell 199580: 573-82.

van Hees PA et al Gut. 198021: 632-5.

Wahl C et al J Clin invest. 1998101: 1163-74.

Wang Y et al, Cochrane Database Syst Rev 2016a 4: CD000543.

Wang Y et al, Cochrane Database Syst Rev. 2016b 5, CD000544.

Zhao W et al, yakugakuzasshi, 2010130: 1239-49.